| Followers | 686 |
| Posts | 142466 |
| Boards Moderated | 35 |
| Alias Born | 03/10/2004 |
Sunday, December 05, 2021 12:17:16 PM
By: MarketBeat | December 3, 2021
• CVS Health (NYSE:CVS)'s stock had its "buy" rating reaffirmed by stock analysts at Seaport Res Ptn in a report released on Wednesday, Zacks.com reports. Seaport Res Ptn also issued estimates for CVS Health's Q4 2021 earnings at $1.57 EPS, FY2021 earnings at $8.00 EPS, Q1 2022 earnings at $2.15 EPS, Q2 2022 earnings at $2.26 EPS, Q3 2022 earnings at $2.07 EPS, Q4 2022 earnings at $1.75 EPS, FY2022 earnings at $8.25 EPS, Q1 2023 earnings at $2.36 EPS, Q2 2023 earnings at $2.46 EPS, Q3 2023 earnings at $2.27 EPS and FY2023 earnings at $9.00 EPS...
Read Full Story »»»
DiscoverGold
Information posted to this board is not meant to suggest any specific action, but to point out the technical signs that can help our readers make their own specific decisions. Caveat emptor!
• DiscoverGold
Recent CVS News
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
